Oruka Therapeutics opened lower at $94.87, compared with its previous close of $96.65. In the last trading session, the stock traded between $94.78 and $97.47. It showed a downward intraday trend.
An investment of $100 made 3 years ago in Oruka Therapeutics is now worth
$ 373.58
giving a profit of
$ 273.58 (273.58%)
Note: Past profits do not guarantee future returns.
Rating from 11 Analysts
Today's Change
$-1.39 (-1.43%)
Day High
$97.47
Day Low
$94.78
Day Open
$94.87
Prev Close
$96.65
Volume
1,93,331
1W Return
17.35%
1M Return
15.93%
3M Return
8.26%
6M Return
39.89%
1Y Return
245.03%
Market Cap ($ Mn)
6,307
PE Ratio
-
PB Ratio
5.00
PEG Ratio
-
ROE
-25.91%
ROCE
-29.70%
EPS (TTM)
-
1 Week
17.35%
1 Month
15.93%
3 Months
8.26%
6 Months
39.89%
9 Months
170.18%
BTIG reiterates Buy on Oruka Therapeutics, keeps $151 target
BTIG analyst Julian Harrison reiterated a Buy rating on Oruka Therapeutics. The price target was maintained at $151. The action reflects continued confidence in the company's outlook.
11 days agoWedbush reiterates Outperform on Oruka Therapeutics with $165 target
Wedbush reiterated an Outperform rating on Oruka Therapeutics. Analyst Martin Fan maintained the $165 price target. The action reflects unchanged valuation assumptions for the stock.
1mo agoOruka Therapeutics reports 71.4% PASI 100 rate for ORKA-001 at Week 28
PASI 100 response rate for ORKA-001 reached 71.4% at Week 28, up from 63.5% at Week 16. PASI 90 response rates climbed to 87.3%, while IGA 0/1 rates held steady at 84.1%. Crossover patients from the placebo arm achieved a 40.0% PASI 100 rate at Week 28. Safety profile remained consistent with the IL-23p19 class, with no injection site reactions observed. Long-term efficacy data from the EVERLAST-A trial is scheduled for release in December 2026.
1mo agoOruka Therapeutics to present at 2026 Morgan Stanley healthcare conference
Oruka Therapeutics to attend 2026 Morgan Stanley Global Healthcare Conference. Event scheduled for September 14-16, 2026, in New York. Company develops biologics for plaque psoriasis and hidradenitis suppurativa. Aims for dosing frequency of once or twice a year.
1mo agoOruka Therapeutics appoints Todd Edwards as chief commercial officer
Todd Edwards appointed as Chief Commercial Officer effective August 24, 2026. Edwards brings over 25 years of experience in immunology and dermatology. Previous role included leading ZORYVE franchise transformation at Arcutis Biotherapeutics. Appointment supports commercialization efforts for ORKA-001 and ORKA-002 pipeline.
2mo agoOruka Therapeutics files prospectus for $1 billion mixed shelf offering
Oruka Therapeutics files prospectus for $1 billion mixed shelf offering. Proceeds to be used for general corporate purposes, including acquisitions. Filing allows issuance of debt, equity, warrants, or units. Mixed shelf structure provides flexibility for future capital raises.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 |
An investment of $100 made 3 years ago in Oruka Therapeutics is now worth
$ 373.58
giving a profit of
$ 273.58 (273.58%)
Note: Past profits do not guarantee future returns.
